Columbia University Study Reveals New Causes of Common Lymphoma

August 18, 2022 by Dan McCue
Columbia University Study Reveals New Causes of Common Lymphoma
Columbia University Irving Medical Center in Manhattan, New York. (Photo via Facebook)

NEW YORK — Cancer researchers at Columbia University in New York have found a multitude of new genetic mutations that cause a common type of lymphoma.

“Our findings not only show that these mutations can contribute to diffuse large B cell lymphoma, but they identify an approach that should be useful for the analysis of other types of tumors,” said Dr. Riccardo Dalla-Favera, director of the Institute for Cancer Genetics at Columbia University Vagelos College of Physicians and Surgeons, who led the study.

The research team’s full findings were published in the journal Nature.

Diffuse large B cell lymphoma is the most common type of human hematologic malignancy and is fast-growing and aggressive.

Although treatment can now cure about two thirds of patients, the remaining patients have poor outcomes and new treatment strategies are needed, the university said in a press release.

Until now, what researchers knew about DLBCL was based on lymphoma-causing mutations found in the genome’s protein-coding genes. It was a logical place to begin, since these genes contain the instructions (or code) for making proteins, which carry out most of a cell’s functions.

But 98% of the human genome does not contain code for making proteins. Previously mischaracterized as “junk,” non-coding DNA is now known to have many functions, including critical roles in the regulation of gene expression.

In the new study, the Columbia researchers found that certain areas of the non-coding genome — called super-enhancers — are mutated in more than 90% of DLBCL tumors and may be necessary to sustain the cancer. Super-enhancers control the expression of one or more genes in the same chromosome.

The researchers found that the genetic correction of specific recurrent mutations within these distinct super-enhancers restored the regulation of the cancer-causing genes and led to tumor death, indicating that the tumor was dependent on the mutated super-enhancers.

The findings also reveal a new level of genetic complexity behind DLBCL that could help explain why this cancer has many different subtypes with diverse behaviors, the research hospital said.
Dan can be reached at [email protected] and at https://twitter.com/DanMcCue.

A+
a-
  • cancer research
  • Columbia University
  • genetic mutations
  • Lymphoma
  • In The News

    Health

    Voting

    Health

    Biden Announcing New Rule to Protect Consumers Who Purchase Short-Term Health Insurance Plans

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A... Read More

    President Joe Biden on Thursday announced new steps to protect consumers who buy short-term health insurance plans that critics say amount to junk. A new rule finalized by the Democratic president's administration will limit these plans to just three months. And the plans can only be renewed for a maximum... Read More

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    News From The Well
    scroll top